These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2569803)

  • 41. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study.
    Glazer WM; Morgenstern H; Doucette JT
    Br J Psychiatry; 1991 Jun; 158():822-8. PubMed ID: 1678663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Depressive states occurring during the neuroleptic treatment of schizophrenia.
    Möller HJ; von Zerssen D
    Schizophr Bull; 1982; 8(1):109-17. PubMed ID: 6122264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Compliance issues in outpatient treatment.
    Kane JM
    J Clin Psychopharmacol; 1985 Jun; 5(3 Suppl):22S-27S. PubMed ID: 2860139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Can psycho-education of chronic schizophrenic patients have a short-term effect on drug-related attitude and behavior?].
    Hornung WP; Franzen U; Lemke R; Wiesemann C; Buchkremer G
    Psychiatr Prax; 1993 Jul; 20(4):152-4. PubMed ID: 8103230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Depot neuroleptic therapy: an underutilized treatment option.
    Glazer WM; Kane JM
    J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Schizophrenic patients' experiences of neuroleptic medication: a Q-methodological investigation.
    Day JC; Bentall RP; Warner S
    Acta Psychiatr Scand; 1996 May; 93(5):397-402. PubMed ID: 8792911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-dose depot medication in schizophrenia.
    Burnett PL; Galletly CA; Moyle RJ; Clark CR
    Schizophr Bull; 1993; 19(1):155-64. PubMed ID: 8095736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Domain-specific subjective quality of life and illness-related limitations of chronic schizophrenic patients].
    Lauer G; Stegmüller-Koenemund U
    Psychiatr Prax; 1994 Mar; 21(2):70-3. PubMed ID: 7910973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ICI 204,636: a new atypical antipsychotic drug.
    Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
    Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
    [No Abstract]   [Full Text] [Related]  

  • 53. Large variations of plasma levels during maintenance treatment with depot neuroleptics.
    Tuninger E; Levander S
    Br J Psychiatry; 1996 Nov; 169(5):618-21. PubMed ID: 8932892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Positive and negative symptoms during neuroleptic treatment.
    Kramer MS
    Biol Psychiatry; 1991 Mar; 29(6):620-1. PubMed ID: 1675891
    [No Abstract]   [Full Text] [Related]  

  • 55. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 56. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia.
    Liddle PF; Barnes TR; Speller J; Kibel D
    Br J Psychiatry; 1993 Dec; 163():776-80. PubMed ID: 7905774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Depot neuroleptic therapy: clinical considerations.
    Remington GJ; Adams ME
    Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical findings. Abnormalities of the mental state and movement disorder and their correlates.
    Johnstone EC; Owens DG; Frith CD; Leary J
    Br J Psychiatry Suppl; 1991 Oct; (13):21-5, 44-6. PubMed ID: 1688117
    [No Abstract]   [Full Text] [Related]  

  • 59. Negative symptoms of schizophrenia and compliance with medication.
    Tattan TM; Creed FH
    Schizophr Bull; 2001; 27(1):149-55. PubMed ID: 11215543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine.
    Bacher NM; Sanzone MM; Kaup B
    J Clin Psychopharmacol; 1994 Dec; 14(6):424-5. PubMed ID: 7884024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.